MouthLab is built on three established pillars: enamel remineralization via nano-hydroxyapatite, selective oral microbiome support, and the gut-oral axis. What follows is the research that drove us to build this.
Every day, your enamel loses minerals to acids from food, bacteria, and reflux. Saliva and dietary minerals work to replace them. When the loss outpaces replacement, the result is demineralization — the precursor to caries. Remineralization is the process of restoring lost mineral content.
Dental enamel is a hydroxyapatite crystal matrix. When the oral environment drops below pH 5.5, the crystal surface dissolves — calcium and phosphate ions diffuse out into saliva. This happens after meals, after sugary or acidic drinks, and in people with reduced salivary flow. Repeated cycles of demineralization outpace natural repair, and the result is white spot lesions — the first visible stage of enamel caries.
Saliva provides some buffering and mineral supply, but its capacity is limited. Under high acid challenge, it cannot keep pace. This is where a remineralizing agent changes the equation.
Fluoride works by catalyzing the precipitation of calcium and phosphate ions into fluorapatite — a more acid-resistant crystal than natural hydroxyapatite. It is effective when salivary ion availability is high. When it is not, fluoride has little to work with.
Fluoride's efficacy depends on concentration, exposure time, and the individual's salivary chemistry. In low-saliva environments — common in people with dry mouth, heavy coffee consumption, or high-stress lifestyles — the mechanism falls apart. Fluoride is a catalyst without sufficient substrate.
Nano-hydroxyapatite particles are sized at approximately 20 nanometers — small enough to penetrate enamel microporosities created by demineralization. They do not require salivary ion availability to work. They carry their own calcium and phosphate payload directly into the lesion and integrate with the natural apatite crystal structure.
This is biomimetic repair: mimicking what the body does naturally, at a scale the body cannot achieve alone. Multiple clinical studies have found n-HAp comparable or superior to fluoride for remineralization. (Amaechi et al., 2019; Najibfard et al., 2011; Grewal et al., 2018; Hassan et al., 2023)
| Mechanism | Fluoride | n-HAp |
|---|---|---|
| How it works | Speeds up ion precipitation from saliva into fluorapatite | Delivers minerals directly into the lesion; integrates with natural crystal |
| Saliva dependency | High — needs available Ca2+/PO4³- in the oral environment | Low — particles carry their own mineral payload |
| Lesion penetration | Surface-level | Penetrates microporosities |
| Efficacy evidence | Decades of data | Comparable or superior in RCTs (Amaechi 2019, Grewal 2018) |
| pH threshold for action | Requires near-neutral pH to work | Works across a wider pH range |
| Biomimetic | No — creates a synthetic crystal | Yes — identical to natural enamel mineral |
The human oral cavity hosts over 700 bacterial species. Most are not pathogens — they are the front line. Treating all bacteria as the enemy is the foundational mistake of broad-spectrum antiseptic mouthwash.
Streptococcus mutans is the primary caries pathogen. It metabolizes sucrose into glucans — sticky extracellular polymers that cement bacteria to enamel, forming biofilm. It produces lactic acid that lowers plaque pH, and it thrives in the acidic conditions it creates. Under a high-sugar, high-frequency diet, S. mutans can dominate.
But S. mutans is not inherently pathological in a balanced ecosystem. It is one player in a community of 700. The pathology emerges when the community structure breaks down — when commensals are suppressed and pathobionts lose their competitors.
Commensal streptococci — particularly S. sanguinis, S. gordonii, and S. salivarius — produce hydrogen peroxide (H₂O₂) that suppresses S. mutans and other pathogens. They metabolize arginine via the arginolytic pathway, generating ammonia that buffers oral pH. They compete for the same adhesion sites S. mutans would otherwise monopolize.
They are the defense mechanism. Their presence is associated with periodontal health, lower caries rates, and better outcomes across oral disease indices. (Burton et al., 2022)
Chlorhexidine (0.12% CHX), the gold standard in clinical antiseptic rinses, is broad-spectrum. A 2025 ex vivo study using a multispecies biofilm model found that CHX severely suppressed regrowth of both commensal streptococci and S. mutans. Recovery of the commensal community was impaired even 72 hours after exposure. Listerine showed similar suppression of regrowth across all tested species. (Frontiers in Oral Health, 2025)
The implication is uncomfortable: antiseptic mouthwash is not selectively suppressing pathogens. It is suppressing the entire community, including the beneficial members that suppress pathogens naturally.
The oral microbiome plays a role in nitric oxide (NO) signaling — the same pathway targeted by some blood pressure medication. Nitrate from dietary greens is concentrated in saliva by the salivary glands. Oral bacteria reduce nitrate to nitrite, which is then reduced to NO in the bloodstream.
Antibacterial mouthwash kills the nitrate-reducing commensals (Veillonella, Selenomonas, Actinomyces) that drive this pathway. Studies have found that twice-daily antiseptic mouthwash use is associated with elevated blood pressure and impaired NO signaling. (Joshipura et al., 2018; Sedghi et al., 2021)
10 Joshipura K et al. (2018) "Insufficient nitrate intake and antibacterial mouthwash." JADA.
9 Sedghi L et al. (2021) Periodontology 2000 87:1.
Produces glucans, acidifies plaque, competes out commensals under high sugar frequency. Not always pathological — but dominant when the environment favors it.
Produce H₂O₂, buffer acid via arginine metabolism, antagonize S. mutans adhesion. They ARE the natural defense mechanism of the oral cavity.
Inhibits S. mutans via the PTS transport system without harming commensals. Reduces adhesion and biofilm formation selectively. Not metabolized by most oral streptococci.
Probiotic strains that colonize the oral cavity and compete with pathobionts. Associated with reduced S. mutans counts and improved periodontal markers in clinical trials.
The oral and gut microbiomes share approximately 700 bacterial species. What happens in your mouth does not stay in your mouth. The mechanism of translocation is established. The systemic consequences are documented.
Every day, you swallow approximately one liter of saliva containing oral bacteria. Most are killed by gastric acid, but not all. Species with sufficient acid tolerance — or that arrive in sufficient numbers — survive transit and reach the intestinal lumen.
Under normal conditions, the intestinal barrier prevents these organisms from causing systemic issues. Under conditions of compromised gut permeability — a common feature of modern Western diets, chronic stress, and antibiotic use — oral pathobionts can adhere to intestinal mucosa, disrupt local microbial communities, and trigger immune responses.
Porphyromonas gingivalis — the primary driver of periodontal disease. Translocates via swallowing and has been found in atherosclerotic plaques, synovial fluid, and brain tissue. Associated with reduced Akkermansia muciniphila abundance (a key protective gut species) and accelerated atherosclerosis. (npj Biofilms and Microbiomes, 2025)
Fusobacterium nucleatum — abundant in periodontitis. Elevated gut abundance correlates with worse outcomes in myocardial ischemia-reperfusion injury. Associated with increased Lactobacillus in the gut and higher systemic inflammatory markers. (Cardiovascular Diabetology, Li et al., 2024)
Klebsiella spp. — oral Klebsiella strains are distinct from gut-adapted pathobionts. They adhere to inflamed intestinal mucosa via CUP pili, outcompete SCFA-producing bacteria, and trigger systemic inflammation. (Guo et al., 2024, Frontiers in Cellular and Infection Microbiology)
The mechanism is LPS translocation. Lipopolysaccharide from Gram-negative oral pathobionts that breach the gut barrier triggers low-grade endotoxemia and chronic systemic inflammation. This is a driver of insulin resistance, atherosclerosis progression, and the inflammatory state underlying cardiovascular disease. (Lankelma et al., 2020, Circulation Research)
This is not fringe science. The oral-gut axis is documented across cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, and neurodegenerative conditions. The direction of causation — mouth to gut, not the reverse — is supported by animal models and human observational data.
Products that support oral microbiome composition — probiotic strains, prebiotic fibers, selective agents like xylitol — may reduce the downstream inflammatory load on the gut. Conversely, supporting gut transit and barrier function may reduce the severity of oral pathobiont overgrowth feedback. MouthLab targets both.
P. gingivalis reduces Akkermansia and accelerates plaque development. Detected in atherosclerotic lesions. (npj Biofilms and Microbiomes, 2025)
LPS translocation drives chronic inflammation. Gut barrier dysfunction in heart failure patients documented in Lankelma et al., 2020.
A double-blind, randomized controlled trial in adults found a hydroxyapatite toothpaste demonstrated significant caries-preventing effect over 18 months compared to a non-fluoridated control. Published in Frontiers in Public Health.
15% hydroxyapatite oral care gel compared against 12,500 ppm fluoride gel in an in-situ caries model. Equivalent efficacy in lesion reduction. Published in BDJ Open.
Comprehensive review establishing commensal streptococci as the primary defensive community of the oral cavity. Their depletion — including by antiseptic rinses — removes a natural barrier to pathogenic overgrowth.
Early access to the science of a healthier mouth. No spam, no filler. Just the products and the research behind them.
No credit card required. Unsubscribe anytime.